Considering pediatric sarcomas, our team previously reported that abundance of hypoxic markers (specifically SLC2A1 and CA9) in rhabdomyosarcoma characterized aggressive tumors resistant to neoadjuvant chemotherapy [22]. This evidence concerns the gene CA9 and rhabdomyosarcoma.